PHARM GROUP 7 Flashcards
WHAT ARE THE MAIN PHARMACOLOGIC CLASSES USED TO TREAT HTN ?
DIURETICS:
- PROMOTE SODIUM RETENTION, REDUCING ECF VOLUME
SYMPATHOLYTICS:
-AFFECT THE SNS TO LOWER BP
DIRECT-ACTING ARTERIOLAR VASODILATORS:
- RELAX VASCULAR SMOOTH MUSCLE, REDUCING BP
ACE INHIBITORS:
- INHIBIT THE CONVERSION OF ANGIOTENSIN 1 TO ANGIOTENSIN 2, REDUCING VASOCONSTRICTION
ARB’S:
- BLOCK ANGIOTENSIN 2 AT THE RECEPTOR, REDUCING VASOCONSTRICTION AND ALDOSTERONE SECRETION
CALCIUM CHANNEL BLOCKERS:
- REDUCE CALCIUM INFLUC INTO HEART AND VASCULAR CELLS, DECREASING CARDIAC CONTRACTILITY AND VASCULAR TONE
WHAT IS THE MOST COMMONLY USED DIURETIC FOR HTN ?
HYDROCHLOROTHIAZIDE
AVOIDED IN PATIENTS WITH RENAL INSUFFICIENCY
WHAT IS THE MOA OF INDIRECT ACTING CHOLINERGIC DRUGS ?
INHIBIT ACETYLCHOLINESTERASE, THE ENZYME THAT BREAKS DOWN ACETYLCHOLINE, THEREBY INCREASING THE AVAILABILITY OF ACETYLCHOLINE TO ACTIVATE RECEPTORS
WHAT ARE THE NONPHARMACOLOGIC MEASURES TO CONTROL HTN ?
STRESS REDUCTION:
- MEDITATION AND RELAXATION CAN LOWER BP
EXERCISE:
- REGULAR AEROBIC EXERCISE IMPROVES CV HEALTH AND DECREASES BP
SALT RESTRICTION:
- LIMITING SALT INTAKE TO <2G/DAY HELPS PREVENT WATER RETENTION AND LOWERS BP
ALCOHOL MODERATION:
- LIMITING ALCOHOL LOWERS BP BY REUDCING RENIN SECRETION
WEIGHT LOSS:
- DECREASE IN BODY WEIGHT HELPS DECREASE CARDIAC OUTPUT AND PERIPHERAL RESISTANCE, WHICH DECREASES BP
PURPOSES AND COMMON FORMS OF SYNTHETIC DERIVATIVES OF TESTOSTERONE
IMPROVE PHARMACOKINETICS AND PHARMACODYNAMICS
COMMON FORMS:
- TESTOSTERONE PROPIONATE
(OILY SOLUTION, LASTS 2-3 DAYS)
- METHYLTESTOSTERONE
(ORAL/BUCCAL FORM)
INDICATIONS FOR HYDROCHLOROTHIAZIDE (HYDRODIURIL)
HTN AND CHF
WHAT IS OXYBUTYNIN (DITROPAN) USED FOR AND WHAT ARE THE NURSING CONSIDERATIONS FOR ITS PATCH APPLICATION ?
USED TO TREAT OVERACTIVE BLADDER AND NEUROGENIC BLADDER CONDITIONS
NURSING CONSIDERATIONS FOR THE PATCH:
- REMOVING THE PREVIOUS DOSE
- APPLYING TO CLEAN, DRY, NONHAIRY SKIN
- ROTATING SITES TO PREVENT SKIN IRRITATION
WHAT IS OSTEOPOROSIS AND ITS KEY GOALS FOR TREATMENT ?
A CONDITION CHARACTERIZED BY A DECREASE IN BONE DENSITY AND AN INCREASE IN FRACTURE RISK DUE TO WEAKENED BONES
KEY GOALS OF TREATMENT ARE TO INCREASE BONE DENSITY AND DECREASE FRACTURE RISK
4 MAIN PARTS OF THE NEPHRON
- GLOMERULUS (FILTRATION)
- PROXIMA CONVOLUTED TUBULE
- LOOP OF HENLE
- DISTAL CONVOLUTED TUBULE
WHAT IS TOLTERODINE (DETROL) USED FOR AND WHAT IS A SIGNIFICANT INTERACTION TO AVOID ?
TREATS URINARY FREQUENCY, URGENCY, AND URGE INCONTINENCE
PATIENTS SHOULD AVOID GRAPEFRUIT JUICE BECAUSE IT CAN ENHANCE THE TOXICITY OF THE DRUG THROUGH THE CYTOCHROME P-450 3A4 LIVER PATHWAY
WHAT IS ESSENTIAL HTN AND HOW COMMON IS IT ?
AKA PRIMARY HTN
HAS NO IDENTIFIABLE CAUSE AND IS THE MOST COMMON TYPE, ACCOUNTING FOR ABOUT 90% OF ALL HTN CASES
ADVERSE EFFECTS OF SPIRONOLACTONE
- HYPERKALEMIA
- GYNECOMASTIA
- HEADACHE
- DIZZINESS
- CRAMPS
PERI-MENOPAUSE
THE TRANSITIONAL PERIOD LEADING UP TO MENOPAUSE. CHARACTERIZED BY FLUCTUATING HORMONE LEVELS
SYMPTOMS
- CYCLES BECOME IRREGULAR
- INSOMNIA
- HOT FLASHES
- IRRITABILITY
- HEADACHES
- MEMORY LAPSES
- DECREASED LIBIDO
- VAGINAL DRYNESS
- JOINT ACHES AND PAINS
PREMARIN (CONJUGATED ESTROGEN)
INDICATIONS:
- HRT FOR MENOPAUSE SYMPTOMS
- MODERATE TO SEVERE VASOMOTOR SYMPTOMS OF MENOPAUSE, VAGINAL DRYNESS, AND ATROPHY
MOA:
- DEVELOPS AND MAINTAINS FEMALE GENITAL SYSTEM, BREASTS, AND SECONDARY SEX CHARACTERISTICS
CONTRAINDICATIONS:
- KNOWN DRUG ALLERGY
- ESTROGEN DEPENDENT CANCERS SUCH AS BREAST CANCER
- UNDIAGNOSED ABNORMAL VAGINAL BLEEDING
- PREGNANCY AND LACTATION
- ACTIVE THROMBOLYTIC DISORDERS (STROKE, THROMBOPHLEBITIS, HYPERCOAGULABLE STATES)
HOW DOES HTN VARY AMONG DIFFERENT ETHNIC GROUPS ?
BLACKS:
- DEVELOP HTN EARLIER WITH HIGHER MORTALITY RATES. THEY HAVE LOW- RENIN HTN WHICH MAKES BETA BLOCKERS AND ACE INHIBITORS LESS EFFECTIVE. ALPHA-BLOCKERS, DIURETICS AND CALCIUM CHANNEL BLOCKERS ARE MORE EFFECTIVE
ASIANS:
- HAVE A HIGHER SENSITIVITY TO BETA-BLOCKERS AND OTHER ANTIHYPERTENSIVE MEDS, SO LOWER DOSES ARE OFTEN REQUIRED
INDIANS:
- SHOW RESISTANCE TO BETA BLOCKERS, NECESSITATING THE USE OF OTHER CLASSES OF HYPERTENSIVES